Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11399679 | 0.97 | KDM4E (0.58) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL11399683 | 0.89 | KDM4E (0.50) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL11096921 | 0.86 | MEN1 (0.59) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL11245497 | 0.85 | MAPT (0.50) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL16117950 | 0.84 | KDM4E (0.69) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL7679338 | 0.83 | KDM4E (0.57) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL3843267 | 0.83 | MEN1 (0.60) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL11395281 | 0.83 | KDM4E (0.50) | KDM4EHTTMEN1KMT2AHSD17B10 | |
| SCHEMBL5579936 | 0.81 | HTT (0.69) | KDM4EHTTTSHRMEN1KMT2A | |
| SCHEMBL11473646 | 0.80 | KDM4E (0.61) | KDM4EHTTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2114898-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | Amgen Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-6413966-B1 | SEROTONERGIC AND CENTRAL DOPAMINERGIC ACTIVITY; AFFINITY FOR 5HT1A AND 5HT2 SEROTONIN AND D2 DOPAMINE RECEPTORS; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. | 2002-07-02 | — | — | US | disclosed |
| EP-1057820-A1 | Arylpiperazinylalkyl-3(2H)-pyridazinones as serotonin 5HT and dopamine D2 receptor agonists | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-12-06 | — | — | EP | disclosed |
| US-4397854-A | INCREASE IN MYOCARDIAL CONTRACTILITY | WARNER-LAMBERT COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | KDM4E 2602/4885HTT 562/4885TSHR 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.